Tamoxifen for the Treatment of Myeloproliferative Neoplasms: A Phase II Clinical Trial and Exploratory Analysis

TAMARIN Phase-II, multicenter, single-arm clinical trial assessed tamoxifen’s safety and activity in patients with stable myeloproliferative neoplasms, no prior thrombotic events and mutated JAK2V617F, CALRins5 or CALRdel52 peripheral blood allele burden ≥20%.